{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T12:55:57Z","timestamp":1781873757655,"version":"3.54.5"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T00:00:00Z","timestamp":1781740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T00:00:00Z","timestamp":1781827200000},"content-version":"vor","delay-in-days":1,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Nephrol"],"DOI":"10.1186\/s12882-026-05071-0","type":"journal-article","created":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T14:54:02Z","timestamp":1781794442000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Serum CXCL10 as a potential biomarker for lupus nephritis and disease activity: evidence from an Egyptian cohort"],"prefix":"10.1186","volume":"27","author":[{"given":"Fatma Mohammed","family":"Badr","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dalia Mohamed","family":"Gamal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ghada Maged","family":"Mohsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammed Abd El Monem","family":"Teama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,18]]},"reference":[{"issue":"12","key":"5071_CR1","doi-asserted-by":"publisher","first-page":"2221","DOI":"10.1007\/s00296-023-05469-1","volume":"43","author":"M Arrucha-Cozaya","year":"2023","unstructured":"Arrucha-Cozaya M, Zamora-Z\u00fa\u00f1iga NC, Miranda-Hern\u00e1ndez D, Bustamante-Gonz\u00e1lez R, Mart\u00ednez-D\u00edaz G, Tovar-Rodr\u00edguez D, et al. In-hospital mortality and associated factors in patients with systemic lupus erythematosus: analysis over more than 11 years in a reference hospital center. Rheumatol Int. 2023;43(12):2221\u201331. https:\/\/doi.org\/10.1007\/s00296-023-05469-1.","journal-title":"Rheumatol Int"},{"key":"5071_CR2","first-page":"221","volume":"29","author":"KK Bechler","year":"2023","unstructured":"Bechler KK, Stolyar L, Steinberg E, Posada J, Minty E, Shah NH. Predicting patients who are likely to develop lupus nephritis among those newly diagnosed with systemic lupus erythematosus. AMIA Annu Symp Proc. 2023;29:221\u201330.","journal-title":"AMIA Annu Symp Proc"},{"issue":"11","key":"5071_CR3","doi-asserted-by":"publisher","first-page":"1496","DOI":"10.1136\/ard-2023-224197","volume":"82","author":"J-YE Lee","year":"2023","unstructured":"Lee J-YE, Mendel A, Askanase A, Bae S-C, Buyon JP, Clarke AE, et al. Systemic lupus erythematosus women with lupus nephritis in pregnancy therapeutic challenge (SWITCH): the systemic lupus international collaborating clinics experience. Ann Rheumatic Dis. 2023;82(11):1496\u201397. https:\/\/doi.org\/10.1136\/ard-2023-224197.","journal-title":"Ann Rheumatic Dis"},{"issue":"3","key":"5071_CR4","doi-asserted-by":"publisher","first-page":"537","DOI":"10.3390\/genes14030537","volume":"14","author":"Y Esparza Guerrero","year":"2023","unstructured":"Esparza Guerrero Y, V\u00e1zquez Villegas, Nava Valdivia CA, Ponce Guarneros JM, P\u00e9rez Guerrero, Gomez Ramirez EE, et al. Association of the STAT4 gene rs7574865 polymorphism with IFN-\u03b3 levels in patients with systemic lupus erythematosus. Genes. 2023;14(3):537. https:\/\/doi.org\/10.3390\/genes14030537.","journal-title":"Genes"},{"issue":"1","key":"5071_CR5","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1007\/s10238-024-01401-4","volume":"24","author":"J-W Kim","year":"2024","unstructured":"Kim J-W, Ahn M-H, Jung J-Y, Suh C-H, Han JH, Kim H-A. Role of chemokines CXCL9, CXCL10, CXCL11, and CXCR3 in the serum and minor salivary gland tissues of patients with Sj\u00f6gren\u2019s syndrome. Clin Exp Med. 2024;24(1):133. https:\/\/doi.org\/10.1007\/s10238-024-01401-4.","journal-title":"Clin Exp Med"},{"key":"5071_CR6","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/j.ctrv.2017.11.007","volume":"63","author":"R Tokunaga","year":"2018","unstructured":"Tokunaga R, Zhang W, Naseem M, Puccini A, Berger MD, Soni S, et al. CXCL9, CXCL10, CXCL11\/CXCR3 axis for immune activation \u2013 a target for novel cancer therapy. Cancer Treat Rev. 2018;63:40\u201347. https:\/\/doi.org\/10.1016\/j.ctrv.2017.11.007.","journal-title":"Cancer Treat Rev"},{"issue":"11","key":"5071_CR7","doi-asserted-by":"publisher","first-page":"3199","DOI":"10.3390\/jcm11113199","volume":"11","author":"MP Brady","year":"2022","unstructured":"Brady MP, Chava S, Tandon S, Rane MJ, Barati MT, Caster DJ, et al. Serum and urine interferon gamma-induced protein 10 (IP-10) levels in lupus nephritis. JCM. 2022;11(11):3199. https:\/\/doi.org\/10.3390\/jcm11113199.","journal-title":"JCM"},{"issue":"8","key":"5071_CR8","doi-asserted-by":"publisher","first-page":"1368","DOI":"10.1002\/iid3.1368","volume":"12","author":"S Wang","year":"2024","unstructured":"Wang S, Cui Y. Clinical significance of serum CXCL9, CXCL10, and CXCL11 in patients with lupus nephritis. Immun Inflam Disease. 2024;12(8):1368. https:\/\/doi.org\/10.1002\/iid3.1368.","journal-title":"Immun Inflam Disease"},{"issue":"8","key":"5071_CR9","doi-asserted-by":"publisher","first-page":"2677","DOI":"10.1002\/art.34473","volume":"64","author":"M Petri","year":"2012","unstructured":"Petri M, Orbai AM, Alarc\u00f3n GS, Gordon C, Merrill JT, Fortin PR, et al. Derivation and validation of the systemic lupus international collaborating clinics classification criteria for systemic lupus erythematosus. Arthritis Rheumatism. 2012;64(8):2677\u201386. https:\/\/doi.org\/10.1002\/art.34473.","journal-title":"Arthritis Rheumatism"},{"issue":"6","key":"5071_CR10","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1136\/heartjnl-2016-309729","volume":"103","author":"AR Opotowsky","year":"2017","unstructured":"Opotowsky AR, Baraona FR, McCausland FR, Loukas B, Landzberg E, Landzberg MJ, et al. Estimated glomerular filtration rate and urine biomarkers in patients with single-ventricle fontan circulation. Heart. 2017;103(6):434\u201342. https:\/\/doi.org\/10.1136\/heartjnl-2016-309729.","journal-title":"Heart"},{"issue":"2","key":"5071_CR11","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1111\/j.1523-1755.2004.00443.x","volume":"65","author":"JJ Weening","year":"2004","unstructured":"Weening JJ, D\u2019Agati VD, Schwartz MM, Seshan SV, Alpers CE, Appel GB, et al. The classification of glomerulonephritis in systemic lupus erythematosus revisited. Kidney Int. 2004;65(2):521\u201330. https:\/\/doi.org\/10.1111\/j.1523-1755.2004.00443.x.","journal-title":"Kidney Int"},{"issue":"2","key":"5071_CR12","first-page":"288","volume":"29","author":"DD Gladman","year":"2002","unstructured":"Gladman DD, Iba\u00f1ez D, Urowitz MB. Systemic lupus erythematosus disease activity index 2000. J Rheumatol. 2002;29(2):288\u201391.","journal-title":"J Rheumatol"},{"issue":"7","key":"5071_CR13","doi-asserted-by":"publisher","first-page":"1354","DOI":"10.1002\/1529-0131(199907)42:7<1354::AID-ANR8>3.0.CO;2-4","volume":"42","author":"HI Brunner","year":"1999","unstructured":"Brunner HI, Feldman BM, Bombardier C, Silverman ED. Sensitivity of the systemic lupus erythematosus disease activity index, British Isles lupus assessment group index, and systemic lupus activity measure in the evaluation of clinical change in childhood-onset systemic lupus erythematosus. Arthritis Rheumatism. 1999;42(7):1354\u201360. https:\/\/doi.org\/10.1002\/1529-0131(199907)42:7%3C1354::AID-ANR8%3E3.0.CO;2-4.","journal-title":"Arthritis Rheumatism"},{"issue":"3","key":"5071_CR14","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1002\/art.1780390303","volume":"39","author":"D Gladman","year":"1996","unstructured":"Gladman D, Ginzler E, Goldsmith C, Fortin P, Liang M, Sanchez-Guerrero J, et al. The development and initial validation of the systemic lupus international collaborating clinics\/American College of Rheumatology damage index for systemic lupus erythematosus. Arthritis Rheumatism. 1996;39(3):363\u201369. https:\/\/doi.org\/10.1002\/art.1780390303.","journal-title":"Arthritis Rheumatism"},{"issue":"7","key":"5071_CR15","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1016\/j.reuma.2023.03.002","volume":"19","author":"PN Brito","year":"2023","unstructured":"Brito PN, Barros DP, Brito BN, Silva RB, Maciel MEC, de Sousa MCN. Systemic lupus erythematosus mimicking leprosy: a challenge to early diagnosis. Reumatolog\u00eda Cl\u00ednica. 2023;19(7):404\u201306. https:\/\/doi.org\/10.1016\/j.reuma.2023.03.002.","journal-title":"Reumatolog\u00eda Cl\u00ednica"},{"key":"5071_CR16","unstructured":"Cuello LN, Perdomo W, Walgamage T, Walgamage M, Raut R, Walgamage MB. Unmasking renal disease in systemic lupus erythematosus: beyond lupus nephritis. Cureus. 2023;15(8)."},{"key":"5071_CR17","doi-asserted-by":"publisher","first-page":"984613","DOI":"10.3389\/fneph.2022.984613","volume":"2","author":"G Moroni","year":"2022","unstructured":"Moroni G, Calatroni M, Ponticelli C. Severe lupus nephritis in the present days. Front. Nephrol. 2022;2:984613. https:\/\/doi.org\/10.3389\/fneph.2022.984613.","journal-title":"Front. Nephrol"},{"issue":"11","key":"5071_CR18","doi-asserted-by":"publisher","first-page":"1237","DOI":"10.1177\/09612033231201619","volume":"32","author":"J Wang","year":"2023","unstructured":"Wang J, Zhu M, Jiao C, Xu X, Xu F, Liang D, et al. Association of regulatory T cells with renal outcomes in patients with proliferative lupus nephritis. Lupus. 2023;32(11):1237\u201344. https:\/\/doi.org\/10.1177\/09612033231201619.","journal-title":"Lupus"},{"key":"5071_CR19","doi-asserted-by":"publisher","unstructured":"Aljaberi N, Wenderfer SE, Mathur A, Qiu T, Jose S, Merritt A, et al. Clinical measurement of lupus nephritis activity is inferior to biomarker-based activity assessment using the renal activity index for lupus nephritis in childhood-onset systemic lupus erythematosus. Lupus Sci Med. 2022;9(1):e000631. https:\/\/doi.org\/10.1136\/lupus-2021-000631.","DOI":"10.1136\/lupus-2021-000631"},{"issue":"1","key":"5071_CR20","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1146\/annurev-med-043021-032611","volume":"74","author":"S Lazar","year":"2023","unstructured":"Lazar S, Kahlenberg JM. Systemic lupus erythematosus: new diagnostic and therapeutic approaches. Annu Rev Med. 2023;74(1):339\u201352. https:\/\/doi.org\/10.1146\/annurev-med-043021-032611.","journal-title":"Annu. Rev. Med"},{"key":"5071_CR21","doi-asserted-by":"publisher","unstructured":"Kameda M, Otsuka M, Chiba H, Kuronuma K, Hasegawa T, Takahashi H, et al. CXCL9, CXCL10, and CXCL11; biomarkers of pulmonary inflammation associated with autoimmunity in patients with collagen vascular diseases\u2013associated interstitial lung disease and interstitial pneumonia with autoimmune features. PLoS One. 2020;15(11):e0241719. https:\/\/doi.org\/10.1371\/journal.pone.0241719.","DOI":"10.1371\/journal.pone.0241719"},{"key":"5071_CR22","doi-asserted-by":"publisher","first-page":"1052917","DOI":"10.3389\/fmicb.2022.1052917","volume":"13","author":"X Yu","year":"2022","unstructured":"Yu X, Chen Y, Cui L, Yang K, Wang X, Lei L, et al. CXCL8, CXCL9, CXCL10, and CXCL11 as biomarkers of liver injury caused by chronic hepatitis B. Front Microbiol. 2022;13:1052917. https:\/\/doi.org\/10.3389\/fmicb.2022.1052917.","journal-title":"Front Microbiol"},{"issue":"1","key":"5071_CR23","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1038\/s41392-024-02018-5","volume":"9","author":"Q Zhang","year":"2024","unstructured":"Zhang Q, Shan Y, Shen L, Ni Q, Wang D, Wen X, et al. Renal remodeling by CXCL10-CXCR3 axis-recruited mesenchymal stem cells and subsequent IL4I1 secretion in lupus nephritis. Sig Transduct Target Ther. 2024;9(1):325. https:\/\/doi.org\/10.1038\/s41392-024-02018-5.","journal-title":"Sig Transduct Target Ther"},{"issue":"2","key":"5071_CR24","doi-asserted-by":"publisher","first-page":"251","DOI":"10.3390\/life12020251","volume":"12","author":"MG Geneva-Popova","year":"2022","unstructured":"Geneva-Popova MG, Popova-Belova SD, Gardzheva PN, Kraev KI. A study of IFN-\u03b1-induced chemokines CCL2, CXCL10 and CCL19 in patients with systemic lupus erythematosus. Life. 2022;12(2):251. https:\/\/doi.org\/10.3390\/life12020251.","journal-title":"Life"},{"issue":"6","key":"5071_CR25","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.1016\/j.kint.2024.09.007","volume":"106","author":"S Vodehnal","year":"2024","unstructured":"Vodehnal S, Mohan C. Urinary biomarkers for active lupus nephritis that have survived independent validation across cohorts. Kidney Int. 2024;106(6):1135\u201345. https:\/\/doi.org\/10.1016\/j.kint.2024.09.007.","journal-title":"Kidney Int"},{"issue":"15","key":"5071_CR26","doi-asserted-by":"publisher","first-page":"4486","DOI":"10.3390\/jcm13154486","volume":"13","author":"J Kosa\u0142ka-W\u0119giel","year":"2024","unstructured":"Kosa\u0142ka-W\u0119giel J, Dziedzic R, Siwiec-Ko\u017alik A, Spa\u0142kowska M, Milewski M, Wach A, et al. Comparison of clinical and laboratory characteristics in lupus nephritis vs. Non-lupus nephritis patients\u2014A comprehensive retrospective analysis based on 921 patients. JCM. 2024;13(15):4486. https:\/\/doi.org\/10.3390\/jcm13154486.","journal-title":"JCM"},{"issue":"6","key":"5071_CR27","first-page":"389","volume":"13","author":"S Abediazar","year":"2019","unstructured":"Abediazar S, Jafari-Nakhjavani M, Ghorbanihaghjo A, Shekarchi M, Zununi Vahed S. Serum levels of CXCL10 and vitamin D in patients with lupus nephritis. Iran J Kidney Dis. 2019;13(6):389\u201397.","journal-title":"Iran J Kidney Dis"},{"issue":"2","key":"5071_CR28","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1007\/s10067-022-06400-y","volume":"42","author":"D Shi","year":"2023","unstructured":"Shi D, Li Y, Shi X, Yao M, Wu D, Zheng Y, et al. Transcriptional expression of CXCL10 and STAT1 in lupus nephritis and the intervention effect of triptolide. Clin Rheumatol. 2023;42(2):539\u201348. https:\/\/doi.org\/10.1007\/s10067-022-06400-y.","journal-title":"Clin Rheumatol"},{"key":"5071_CR29","doi-asserted-by":"publisher","first-page":"109155","DOI":"10.1016\/j.intimp.2022.109155","volume":"111","author":"X Zhang","year":"2022","unstructured":"Zhang X, Liu C, Yang J, Ren H, Zhang J, Chen S, et al. Potential biomarkers for diagnosis and assessment of disease activity in systemic lupus erythematosus. Int Immunopharmacol. 2022;111:109155. https:\/\/doi.org\/10.1016\/j.intimp.2022.109155.","journal-title":"Int Immunopharmacol"},{"issue":"19","key":"5071_CR30","doi-asserted-by":"publisher","first-page":"4954","DOI":"10.3390\/ijms20194954","volume":"20","author":"P Puapatanakul","year":"2019","unstructured":"Puapatanakul P, Chansritrakul S, Susantitaphong P, Ueaphongsukkit T, Eiam-Ong S, Praditpornsilpa K, et al. Interferon-inducible protein 10 and disease activity in systemic lupus erythematosus and lupus nephritis: a systematic review and meta-analysis. IJMS. 2019;20(19):4954. https:\/\/doi.org\/10.3390\/ijms20194954.","journal-title":"IJMS"},{"issue":"10","key":"5071_CR31","doi-asserted-by":"publisher","first-page":"1639","DOI":"10.1136\/annrheumdis-2012-201586","volume":"72","author":"T Rose","year":"2013","unstructured":"Rose T, Gr\u00fctzkau A, Hirseland H, Huscher D, D\u00e4hnrich C, Dzionek A, et al. IFN\u03b1 and its response proteins, IP-10 and SIGLEC-1, are biomarkers of disease activity in systemic lupus erythematosus. Ann Rheumatic Dis. 2013;72(10):1639\u201345. https:\/\/doi.org\/10.1136\/annrheumdis-2012-201586.","journal-title":"Ann Rheumatic Dis"},{"issue":"9","key":"5071_CR32","doi-asserted-by":"publisher","first-page":"2423","DOI":"10.1007\/s00296-012-2393-5","volume":"33","author":"E Hrycek","year":"2013","unstructured":"Hrycek E, Franek A, B\u0142aszczak E, Dworak J, Hrycek A. Serum levels of selected chemokines in systemic lupus erythematosus patients. Rheumatol Int. 2013;33(9):2423\u201327. https:\/\/doi.org\/10.1007\/s00296-012-2393-5.","journal-title":"Rheumatol Int"},{"issue":"1","key":"5071_CR33","doi-asserted-by":"publisher","first-page":"101805","DOI":"10.1016\/j.reuma.2024.10.006","volume":"21","author":"A Akhil","year":"2025","unstructured":"Akhil A, Bansal R, Kaushal J, Sharma A, Bhatnagar A. Investigating potential biomarkers and therapeutic targets for patients with systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA) through the utilization of cytokine profiling. Reumatolog\u00eda Cl\u00ednica. 2025;21(1):101805. https:\/\/doi.org\/10.1016\/j.reuma.2024.10.006.","journal-title":"Reumatolog\u00eda Cl\u00ednica"},{"issue":"6","key":"5071_CR34","doi-asserted-by":"publisher","first-page":"292","DOI":"10.4081\/reumatismo.2013.719","volume":"65","author":"M Marie","year":"2014","unstructured":"Marie M, Khalil RE, Habib H. Urinary CXCL10: a marker of nephritis in lupus patients. Reumatismo. 2014;65(6):292\u201397. https:\/\/doi.org\/10.4081\/reumatismo.2013.719.","journal-title":"Reumatismo"},{"issue":"4","key":"5071_CR35","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1016\/j.ajme.2018.11.001","volume":"54","author":"MMH Zeid","year":"2018","unstructured":"Zeid MMH, Baddour NM, El-Neily DAEM, Elshair HS, Mamdouh M. Study of urinary interferon gamma-induced protein 10 (IP-10) and urinary soluble CD 25 (sCD25) as markers of lupus nephritis and their relation to histological class. Alexandria J Med. 2018;54(4):647\u201353. https:\/\/doi.org\/10.1016\/j.ajme.2018.11.001.","journal-title":"Alexandria J Med"},{"issue":"1","key":"5071_CR36","doi-asserted-by":"publisher","first-page":"31422","DOI":"10.1038\/s41598-024-83057-4","volume":"14","author":"DJ Park","year":"2024","unstructured":"Park DJ, Joo YB, Nam E, Lee J, Bang SY, Lee HS, et al. Exploring potential multiple molecular biomarkers that predict treatment response in patients with lupus nephritis. Sci Rep. 2024;14(1):31422. https:\/\/doi.org\/10.1038\/s41598-024-83057-4.","journal-title":"Sci Rep"},{"issue":"8","key":"5071_CR37","doi-asserted-by":"publisher","first-page":"1259","DOI":"10.1177\/0961203318770006","volume":"27","author":"B Jakiela","year":"2018","unstructured":"Jakiela B, Kosa\u0142ka J, Plutecka H, W\u0119grzyn AS, Bazan-Socha S, Sanak M, et al. Urinary cytokines and mRNA expression as biomarkers of disease activity in lupus nephritis. Lupus. 2018;27(8):1259\u201370. https:\/\/doi.org\/10.1177\/0961203318770006.","journal-title":"Lupus"},{"issue":"6","key":"5071_CR38","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1007\/s00011-016-0930-5","volume":"65","author":"JY Choe","year":"2016","unstructured":"Choe JY, Kim S-K. Serum TWEAK as a biomarker for disease activity of systemic lupus erythematosus. Inflamm Res. 2016;65(6):479\u201388. https:\/\/doi.org\/10.1007\/s00011-016-0930-5.","journal-title":"Inflamm Res"},{"issue":"6","key":"5071_CR39","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.1002\/jcla.21993","volume":"30","author":"A El-Gohary","year":"2016","unstructured":"El-Gohary A, Hegazy A, Abbas M, Kamel N, Nasef SI. Serum and urinary interferon- gamma-inducible protein 10 in lupus nephritis. J Clin Lab Anal. 2016;30(6):1135\u201338. https:\/\/doi.org\/10.1002\/jcla.21993.","journal-title":"J Clin Lab Anal"}],"container-title":["BMC Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12882-026-05071-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12882-026-05071-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12882-026-05071-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T12:09:23Z","timestamp":1781870963000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12882-026-05071-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,18]]},"references-count":39,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["5071"],"URL":"https:\/\/doi.org\/10.1186\/s12882-026-05071-0","relation":{},"ISSN":["1471-2369"],"issn-type":[{"value":"1471-2369","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,18]]},"assertion":[{"value":"28 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study complied with the Helsinki Declaration and obtained clearance from the Research Ethics Committee of the Faculty of Medicine at Ain Shams University (FMASU REC) (approval registration number: FW00017585\/R 305\/2025). All participants were informed of the research objectives, parameters, and their rights. Informed written consent was secured from all individuals.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"376"}}